Related Experiment Videos

Elevated levels of MMP-9 in untreated patients with stage I essential hypertension

Eugenia Gkaliagkousi1, Michail Doumas, Eleni Gavriilaki

  • 1Second Propedeutic Department of Internal Medicine, Hippokrateion Hospital, Thessaloniki, Greece. eugalant@yahoo.com

Clinical and Experimental Hypertension (New York, N.Y. : 1993)
|May 12, 2012
PubMed

Insights

Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) levels differ in untreated mild essential hypertension. Elevated MMP-9 may indicate cardiovascular risk and vascular dysfunction in early hypertension.

Area of Science:

  • Cardiovascular Science
  • Biochemistry
  • Hypertension Research

Background:

  • Metalloproteinases (MMPs) and their inhibitors (TIMPs) are crucial in vascular remodeling and atherosclerosis.
  • Inflammatory cytokines like IL-6 and TNF-α stimulate MMPs, contributing to cardiovascular disease.
  • Essential hypertension is a major risk factor for cardiovascular complications.

Purpose of the Study:

  • To investigate serum levels of MMP-2, MMP-9, TIMP-1, TIMP-2, IL-6, and TNF-α.
  • To compare these levels between patients with untreated mild essential hypertension (UH) and normotensive (NT) individuals.
  • To determine the potential role of these biomarkers in early hypertension.

Main Methods:

  • Serum samples were collected from UH and NT volunteers.
  • Levels of MMP-2, MMP-9, TIMP-1, TIMP-2, IL-6, and TNF-α were quantified.
  • Statistical analysis was performed to compare biomarker levels between groups.

Main Results:

  • Serum MMP-9 and TIMP-1 levels were significantly elevated in UH patients compared to NT volunteers.
  • No significant differences were reported for MMP-2, TIMP-2, IL-6, and TNF-α between the groups.
  • MMP-9 showed a significant difference in early-stage essential hypertension.

Conclusions:

  • Elevated MMP-9 in early essential hypertension suggests its involvement in vascular dysfunction.
  • MMP-9 may serve as a potential biomarker for cardiovascular risk assessment in hypertensive patients.
  • Further research is warranted to explore the therapeutic implications of targeting MMP-9 in hypertension.

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult body.
A...
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Measurement of Blood Pressure01:17

Measurement of Blood Pressure

Assessing blood pressure is a standard procedure executed in virtually all medical environments. The method utilized today was established over a hundred years ago by an innovative Russian doctor, Dr. Nikolai Korotkoff. The soft ticking noise, known as Korotkoff sounds, heard while taking blood pressure readings results from turbulent blood flow within the vessels. The apparatus required for this procedure includes a sphygmomanometer, a blood pressure cuff attached to a gauge, and a stethoscope.